Soolantra is a topical ivermectin cream for adults with inflammatory rosacea. It is applied to affected facial areas to reduce papules and pustules linked with the condition. Its anti-inflammatory and antiparasitic activity acts close to the skin surface.
Soolantra cream is used for inflammatory rosacea, a chronic facial skin disorder that can cause persistent redness, papules, pustules, burning, and sensitivity. The cream is intended for adults whose rosacea includes raised inflammatory lesions rather than redness alone.
The active ingredient is ivermectin. The product is supplied as a cream in tubes for cutaneous use.
Soolantra contains ivermectin in a cream base. The formulation also contains inactive excipients that give the cream its texture, stability, and spreadability.
The listed excipients include:
Stearyl alcohol and cetyl alcohol are fatty alcohols used to support the cream base. They are different from drying alcohols such as ethanol, although sensitive skin can still react to any cosmetic or pharmaceutical ingredient.
Propylene glycol can cause irritation or contact dermatitis in susceptible individuals. Methyl-4-hydroxybenzoate is a preservative, also known as methylparaben, and may trigger a reaction in people with a known sensitivity to preservatives.
Apply Soolantra once daily to the affected areas of the face. The usual treatment areas are the forehead, nose, chin, and both cheeks when rosacea lesions are present there.
The product is for external use. Do not apply it to broken, infected, or severely inflamed skin unless a prescriber has specifically directed this.
Treatment usually continues for several weeks. Clinical studies assessed improvement during ongoing daily use, and some patients need continued treatment to maintain control. If a dose is missed, apply the next dose at the usual time. Do not apply extra cream to compensate.
Avoid applying strong exfoliating acids, abrasive scrubs, alcohol-heavy toners, or retinoid products at the same time unless they form part of an agreed skincare plan. A bland moisturiser may be used after Soolantra has absorbed if dryness develops.
Soolantra should not be used on children unless a specialist has prescribed it for that specific patient. Keep the tube closed between applications and prevent contact between the applicator opening and the skin.
No routine food interaction is expected with topical Soolantra. Alcohol does not create a recognised direct interaction with the cream, although alcohol can trigger rosacea flushing in some patients.
Do not apply the cream to the breast immediately before feeding. If treatment is needed on breast skin, remove residual cream before the infant feeds.
Ivermectin belongs to the avermectin class of compounds. In topical rosacea treatment, it has both anti-inflammatory and antiparasitic properties. Rosacea is not caused by one single mechanism, but inflammatory immune activity and increased numbers of skin-associated Demodex mites may contribute to lesions in some patients.
Ivermectin acts on glutamate-gated chloride channels in parasites, leading to paralysis and death of the organism. In human skin, the topical formulation also appears to reduce inflammatory signalling associated with rosacea. The result is a gradual reduction in papules and pustules for many treated adults.
Soolantra cream is used for inflammatory rosacea, a chronic facial skin disorder that can cause persistent redness, papules, pustules, burning, and sensitivity. The cream is intended for adults whose rosacea includes raised inflammatory lesions rather than redness alone.
Soolantra focuses on the inflammatory bumps and pustules associated with rosacea. It does not function as a general moisturiser or instant redness-reducing cosmetic.
Topical ivermectin, azelaic acid, and metronidazole are used for inflammatory rosacea, but they act through different pharmacological pathways. Ivermectin may be selected when papules and pustules are prominent or when a mite-related inflammatory contribution is suspected.
Azelaic acid may suit patients who need an alternative anti-inflammatory topical treatment, although tingling and irritation are common during early use. Metronidazole is another established topical option for inflammatory lesions. Oral antibiotics may be considered when disease is more extensive, persistent, or associated with eye involvement, but they bring systemic adverse-effect considerations.
Soolantra may not be suitable if you have had a serious allergic reaction to ivermectin or any ingredient in the cream. Do not use it on broken or infected skin, inside the eyes, on the lips, or inside the nose or mouth. Seek medical advice before using it if your facial lesions have not been assessed as rosacea, or if you have eye pain, visual changes, or light sensitivity. Pregnancy and breastfeeding require an individual risk assessment.
Topical ivermectin is often tolerated well, but treated skin can react during the first weeks. Reported reactions include burning, stinging, irritation, itching, dryness, and worsening of rosacea symptoms. These effects may be mild and temporary, but persistent or severe inflammation needs assessment.
Clinical trial data identified application-site burning and irritation among recognised adverse reactions. The FDA prescribing information also warns that some patients may experience skin reactions during treatment [1].
Possible reactions include:
A small amount of warmth or stinging can occur when the cream is first introduced. Stop applying the product and obtain urgent medical attention if facial swelling, breathing difficulty, widespread hives, blistering, or severe eye symptoms develop.
Clinical improvement can be uneven. One cheek may settle before the nose or chin, and lesions may fluctuate during the first part of treatment. Lack of immediate change does not prove that the cream is unsuitable, but marked deterioration requires review.
Several routine mistakes can make treatment appear ineffective or cause unnecessary irritation:
One subtle mistake is applying moisturiser, sunscreen, and makeup immediately after the cream while rubbing the face repeatedly. This can remove part of the treatment and worsen friction-related redness. Let the cream settle first, then press other products onto the skin rather than massaging aggressively.
Another is judging progress only by colour. Soolantra mainly targets inflammatory lesions. Fewer bumps and pustules may represent a meaningful response even when background redness remains.
In clinical practice, dermatologists usually assess the type of rosacea before selecting a topical medicine. Soolantra is most relevant when raised inflammatory lesions are present. It is less likely to address isolated flushing or established facial thread veins.
Doctors also look for conditions that can resemble rosacea, including acneiform eruptions, seborrhoeic dermatitis, allergic dermatitis, and perioral dermatitis. The treatment plan may change if the diagnosis changes.
The expected response is gradual. Phase 3 trials reported greater reductions in inflammatory lesions with ivermectin cream than with vehicle cream, with assessments made over repeated weeks of treatment [2]. A physician may continue treatment when improvement is present but incomplete, provided the cream is tolerated.
A practical prescribing conversation includes skincare. Daily sun protection, a gentle cleanser, and avoidance of known triggers can reduce the number of variables affecting the skin. Soolantra is one part of management rather than a replacement for trigger control.
Visible improvement may develop over several weeks of consistent once-daily application. Some adults notice fewer inflammatory lesions earlier, while others need longer treatment before the change is clear. The European Medicines Agency's 2015 product information describes ivermectin cream as a treatment requiring regular application rather than a single-use product. Clinical evaluations of topical ivermectin measured outcomes over repeated treatment visits [3]. Response timing varies between individuals.
Soolantra is aimed mainly at inflammatory rosacea lesions such as papules and pustules. Background redness may improve when inflammation settles, but persistent flushing or visible blood vessels may remain. The World Health Organization's 2023 health information describes rosacea as a chronic inflammatory skin condition requiring symptom-directed care. A separate treatment approach may be needed for vascular redness.
A bland moisturiser and broad-spectrum sunscreen can usually form part of a rosacea skincare routine. Apply Soolantra to clean, dry skin, allow it to settle, and then use other products gently. The European Medicines Agency's 2015 product information emphasises topical administration to affected facial skin. Fragrances, abrasive particles, and strong exfoliants are more likely to aggravate sensitive skin than simple moisturising products.
Soolantra is indicated for inflammatory lesions of rosacea, not as a general acne treatment. Acne and rosacea can look similar, but their patterns and treatment plans differ. The American Academy of Dermatology's 2024 clinical guidance separates acne management from rosacea management. New lesions around the mouth, forehead, or jaw should be assessed before changing treatment.
Pregnancy requires an individual discussion about the expected benefit and potential exposure. Topical treatment generally produces less systemic exposure than oral therapy, yet that does not remove the need for a careful decision. The EMA's 2015 product information addresses use during pregnancy and breastfeeding. Do not apply the cream to breast skin immediately before feeding.
Stop applying the cream if severe swelling, blistering, widespread hives, or intense burning develops. Eye pain, facial swelling, breathing difficulty, or visual symptoms require urgent medical attention. The FDA's 2014 product information identifies hypersensitivity and significant skin reactions as reasons for prompt assessment. Mild dryness or brief stinging is different from a rapidly worsening allergic reaction.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I applied the cream once each evening for about four weeks. The bumps around my nose became less frequent, although my cheeks still flushed after hot weather. The first week brought mild dryness, which improved when I stopped using a facial scrub.
The cream was easy to spread and did not leave a heavy residue. I noticed fewer pustules after several weeks, but the improvement was not immediate. I still needed sunscreen because outdoor heat triggered redness.
During the first ten days my skin felt itchy and slightly tight. I reduced the rest of my skincare routine and the irritation settled. The treatment helped the raised spots, but it did not remove all facial redness.
I initially applied too much because I thought a thicker layer would work faster. That caused more stinging around the nose. Using a thin layer once daily was more comfortable.
After several weeks the inflammatory lesions were less noticeable. I continued to have occasional flares after alcohol, so the cream did not eliminate every trigger.
